Angle Share Discussion Threads

[deanmatlazin] 10/10/2022 15:49

Yawwwnnnnnn

[sicilian_kan] 10/10/2022 15:47

Over 20 companies are in contract discussions with Angle at the moment, including 3 household names, plus Abbott (market cap $178bn) are in detailed discussions with Angle that are going very well. But of course you know best don't you, in making spurious suggestions that AN hasn't got a clue what to do post FDA approval.

[1liam] 10/10/2022 15:33

Close below 61p !!!!

[deanmatlazin] 10/10/2022 15:31

honestly i thought the ball start rolling with FDA approval and CEO will be mega busy with announcing hospitals taking up PARSOTIX. It is only transpire that the CEO hasnt got a clue what to do after obtaining FDA. Down from £1.60p to 60p since FDA approval.

What a shamble!

[sicilian_kan] 10/10/2022 14:47

I remember dean you stating:

"once 160p gone this will go up to £2 and upward in no time!"

and

"Current market cap only £368m

Should be £1000m and above. 3 bagger is coming!"

It would be amusing if you got it wrong at both ends :-)

[deanmatlazin] 10/10/2022 14:44

this will go down to 40s-50s.

[divmad] 10/10/2022 14:26

Easy to buy this afternoon. Just picked up 60k at 62.25p. Probably more on offer at that level but that's me done for now.

[amaretto1] 10/10/2022 14:08

Your right ... it's been a journey.. after a 2 year hold ...Most far higher averages ...They drilled the share price in to the ground like here ....

[amaretto1] 10/10/2022 14:06

Yes ... I'm happier with the EVG position...Averaged down to 5 ...Just derisked a few

[1liam] 10/10/2022 13:57

Close below 61p

[zeus19] 10/10/2022 13:49

On 226k volume hahaha ok then

[toffeeman] 10/10/2022 13:47

>> S-K

Still a long way up if you bought EVG at 9.5!!

[1liam] 10/10/2022 13:47

City boys taking it lower.

[sicilian_kan] 10/10/2022 13:43

Worth noting that EVG went up 130% today (sub 3p to over 6.5p) on an ok licensing deal. Shows the market is there when the partnership deals come in.

[tday] 10/10/2022 12:50

Because over 75% by value of shareholders, presently would probably accept far less. 160p would, as likely as not, do it. Maybe if there is more good news, the share price might rise and with it the price any bidders would have to pay. To have a bid of 383p, the share price would be nearer 180p. Just my view.

[clausentum] 10/10/2022 12:38

With 260m shares issued it would only cost Abbott £1B to buy AGL at £3.83 per share, why are they waiting?

[deanmatlazin] 10/10/2022 12:24

Yawwwnnnn. AGL need to get someone experience to roll out PARSOTIX in USA EUROPE and Rest of the world. Pay someone with experience a big money to bring in MEGA money to the company.

But CEO like to go fishing and wait for another trial result to come in. No rush. £20m in the bank. That can support his lifestyle until he retire.

This is going to drip drip drip...to 50s or even 40s. What a shamble after got FDA approval

[purchaseatthetop] 10/10/2022 11:50

Wonder when the lab certification will hit? It was in the final stages a few weeks ago.

[bagpuss67] 10/10/2022 09:38

Couldn't resist another 10k at 64p ie 20% below the placing price Holding more of these now than I have ever done...

[spaceparallax] 10/10/2022 09:17

Happy to sit patiently and wait the massive rewards that are inevitable here.

[sicilian_kan] 10/10/2022 08:56

Current market cap just $167m with likely net cash of today (10 October) of around $46m [£20.5m half year plus £18.9m net proceeds of placing + £5.9m tax credits - 2.5 months x £1.53m cash burn * exchange rate]

This means that the enterprise value is around just $121m for the whole of Angle. The company is absolutely ripe for a takeover.

First FDA approved device for harvesting CTCs for downstream analysis with all competitors many years behind, in fact no where in sight. FDA approval in MBC. Best in class ovarian results. Clearly showing a derisked platform device. Prostate headline results due next year to add to this. In negotiations with over 20 companies for its pharma services with 3 of these companies being household names. Abbott who are cash rich having collaborated with them in the FDA trial and who are looking to get into the liquid biopsy sector via M&A, in particular for devices.

One more point about Abbott. I've noted their increasing cash position before:

$3.8bn cash in 2019
$6.8bn cash in 2020
$9.8bn cash in 2021

I haven't noted that they have done that whilst at the same time having increased their dividend every year for over 50 consecutive years, which is quite astonishing.

To have Abbott as a collaborator, who want to move into the sector and who are so cash rich speaks volumes.

Remember we know from AN at the recent presentation the following, noting the words "detailed" discussions and that discussions are progressing "very well".

Worst case scenario we have a partnership with them, which will increase the share price. Best case scenario they pull the trigger realising that with FDA MBC approval and best in class ovarian that Angle is derisked and at these prices they will do far better to buy the whole company than to partner in just one indication:

"Yes, well they are the leading player for HER-2 testing. It's currently a $600 million dollar market and they're the largest player in that market. So we utilised their downstream PathVysion tests for HER-2 in our FDA submission, and we're now in detailed discussions with Abbott about how we can work with them to bring forward a test combining Parsortix and PathVysion. And those conversations are progressing very well".

[1liam] 10/10/2022 08:55

Still dropping!

[bermudashorts] 09/10/2022 17:20

gooosed,

Yes and of course some assays such as PD-L1 will cross multiple cancer types.